

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Company Registration No.: 91120000103100784F)
(Incorporated in the People's Republic of China)

ANNOUNCEMENT ON THE EVALUATION REPORT ON THE 2024 ACTION PLAN AND ON THE 2025 ACTION PLAN

The board of directors (the “Board”) and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “Company”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

The Board refers to the announcement made by the Company on 16 August 2024 in relation to the 2024 Action Plan for “Quality Improvement, Efficiency Enhancement, and Focus on Shareholder Returns” (2024 年度“提质增效重回报”行动方案) (the “**2024 Action Plan**”).

In order to promote the high-quality development of the Company and deliver better returns to its shareholders, the Company has thoroughly implemented the *Opinions of the State Council on Further Improving the Quality of Listed Companies* (《关于进一步提高上市公司质量的意见》) and actively responded to the *Initiative on Launching the Special Action on “Quality Improvement, Efficiency Enhancement, and Focus on Shareholder Returns” for Companies Listed on the Shanghai Stock Exchange* (《关于开展沪市公司“提质增效重回报”专项行动倡议》) issued by the Shanghai Stock Exchange. On this basis, the Company formulated the 2024 Action Plan and has remained focused on its principal business, while enhancing new quality productive forces (新质生产力), strengthening corporate governance, delivering returns to shareholders, and improving investor communication. The implementation status of the 2024 Action Plan and the details of the Company’s 2025 Action Plan for “Quality Improvement, Efficiency Enhancement, and Focus on Shareholder Returns” (2025 年度“提质增效重回报”行动方案) are set out in **Appendix A** to this announcement.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
25 August 2025

APPENDIX A

2024 年度“提质增效重回报”行动方案的评估报告暨 2025 年度“提质增效重回报”行动方案公告

EVALUATION REPORT ON THE 2024 ACTION PLAN FOR “QUALITY IMPROVEMENT, EFFICIENCY ENHANCEMENT, AND FOCUS ON SHAREHOLDER RETURNS”, AND THE 2025 ACTION PLAN FOR “QUALITY IMPROVEMENT, EFFICIENCY ENHANCEMENT, AND FOCUS ON SHAREHOLDER RETURNS”

为推动公司高质量发展，更好回报投资者，津药达仁堂集团股份有限公司（以下简称“公司”）深入贯彻落实国务院《关于进一步提高上市公司质量的意见》，积极响应上海证券交易所《关于开展沪市公司“提质增效重回报”专项行动倡议》，制定 2024 年度“提质增效重回报”行动方案，公司持续聚焦主业，提升新质生产力，规范治理，回报股东，加强投资者沟通工作。现将公司 2024 年度“提质增效重回报”行动方案落实情况暨 2025 年度“提质增效重回报”行动方案报告如下：

In order to promote the high-quality development of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (the “**Company**”) and to deliver better returns to its shareholders, the Company has thoroughly implemented the *Opinions of the State Council on Further Improving the Quality of Listed Companies* (《关于进一步提高上市公司质量的意见》) and actively responded to the *Initiative on Launching the Special Action on “Quality Improvement, Efficiency Enhancement, and Focus on Shareholder Returns” for Companies Listed on the Shanghai Stock Exchange* (《关于开展沪市公司“提质增效重回报”专项行动倡议》) issued by the Shanghai Stock Exchange (the “**SSE**”). On this basis, the Company formulated the 2024 Action Plan for “Quality Improvement, Efficiency Enhancement, and Focus on Shareholder Returns” (2024 年度“提质增效重回报”行动方案) (the “**2024 Action Plan**”), and has remained focused on its principal business, while enhancing new quality productive forces (新质生产力), strengthening corporate governance, delivering returns to shareholders, and improving investor communication. The implementation status of the 2024 Action Plan and the details of the Company’s 2025 Action Plan for “Quality Improvement, Efficiency Enhancement, and Focus on Shareholder Returns” (2025 年度“提质增效重回报”行动方案) (the “**2025 Action Plan**”) are set out as follows:

一、聚焦核心工业，聚力核心主业

I. Focusing on Core Industry Segment and Strengthening Core Business Operations

2024 年至今，公司持续聚焦资源于中成药工业板块，聚能主品，不断提升品牌力、产品力、服务力。2025 年上半年，公司工业主营收入 26.45 亿元，同比增长 0.87%，其中速效救心丸销售额（含税）11.28 亿元，同比增长 5.45%；清咽滴丸销售额（含税）2.89 亿元，同比增长 52.28%。公司以“达仁堂”主品牌统领市场工作“一路向 C”，持续走向全国，走入消费者心智，公司成功启动“为爱常备，救在身边，达仁堂速效救心公益行动”。达仁堂大国品牌项目登陆央视；圆满承办第十一届中药材基地共建共享交流大会；“中医药文化守护官”已累计覆盖市民近 6000 人；已宣讲 186 场“中医药文化进校园”活动，覆盖超 2 万名师生及家长。

Since 2024, the Company has continued to concentrate its resources on the proprietary Chinese medicine industry segment, with an emphasis on its flagship products, while consistently enhancing its brand strength, product quality, and service excellence. In the first half of 2025, revenue from the Company’s principal industrial operations amounted to approximately RMB2,645 million, representing

a year-on-year increase of 0.87%. Of which, sales (including tax) of Suxiao Jiuxin Wan (速效救心丸) amounted to approximately RMB1,128 million, representing a year-on-year increase of 5.45%, while sales (including tax) of Qingyan Di Wan (清咽滴丸) amounted to approximately RMB289 million, representing a year-on-year increase of 52.28%. Guided by its “Da Ren Tang” master brand and the “All the Way to C” (一路向 C) strategy (with “C” referring to consumers), the Company continued to expand nationwide and strengthen its consumer recognition. The Company initiated the public welfare programme “Be Prepared with Love, Rescue at Hand – Da Ren Tang Suxiao Jiuxin Public Welfare Action” (为爱常备，救在身边，达仁堂速效救心公益行动). The “Da Ren Tang” National Brand Project was featured on CCTV. The Company also hosted the 11th Exchange Conference on Co-construction and Sharing of Chinese Herbal Medicine Bases. In addition, the “Traditional Chinese Medicine Cultural Guardian” (中医药文化守护官) campaign has cumulatively reached nearly 6,000 citizens, while the “Traditional Chinese Medicine Culture in Campus” (中医药文化进校园) programme has held 186 sessions, covering more than 20,000 teachers, students and parents.

公司将旗下全资子公司天津中新医药有限公司的全部股权作价，以增资形式并入津药太平医药有限公司，今年开始不再确认其收入；两次转让所持全部联营公司中美天津史克制药有限公司股权，表观业务结构更加清晰。

In 2024, the Company completed the capital injection into Tianjin Pharmaceutical Group Taiping Medicine Co., Ltd. (津药太平医药有限公司) through the transfer of the 100% equity interest in its wholly-owned subsidiary, Tianjin Zhongxin Medicine Co., Ltd. (天津中新医药有限公司) (“**TJZX Medicine**”), and therefore no longer consolidates the financial results of TJZX Medicine starting from 2025. In addition, the Company completed the disposal of its 25% equity interest in a then associated company, Tianjin TSKF Pharmaceutical Co., Ltd. (中美天津史克制药有限公司), of which 13% was disposed of in the second half of 2024 and the remaining 12% was disposed of during the first half of 2025, resulting in a more streamlined business structure.

2025 年，公司将继续以消费者为中心，持续聚焦资源，聚能主品，不断提升品牌力、产品力、服务力；加强 3S (Sell In 即出货，Sell Through 即分销，Sell Out 即实销) 管理，强化 Sell Out 运营能力，做强主品。

Looking ahead to 2025, the Company will continue to adopt a consumer-centric approach, concentrating its resources on the industry segment, with an emphasis on its flagship products, while further enhancing brand strength, product quality, and service excellence. The Company will also strengthen its 3S management (Sell In – shipments, Sell Through – distribution, Sell Out – actual sales), with a particular emphasis on improving its Sell Out capability, to reinforce the competitiveness of its key products.

二、提升新质生产力，质胜产业新周期

II. Enhancing New Quality Productive Forces and Promoting Industrial Upgrading

2024 年至今，公司聚力实施中药材内控标准统一项目，梳理统一关键质量流程，统一中药材质量内控标准，结合产品特点确定 46 个中药材采购标准高于中国药典标准；已启动《津药达仁堂中药材质量标准(2025)》编写工作，并已完成 100 个品种质量标准初稿的编写；2024 年新建黄连、厚朴两个“三无一全”基地，2025 年上半年完成金银花 GAP 基地天津市药监局延伸检查工作；已完成 5 个产品“说明书适老化”改革并投入市场，创新性实现“数字人视频、电子说明书、语音播报”适老化功能；6 个产品完成立项、延长效期(36 个月)质量稳定性研究和备案审批并投放市场；完成 33 个沉睡品种的恢复计划评估；在 8 个大蜜丸转小蜜丸品种项目中，已完成人参健脾丸和六味地黄丸的生产；痹祺胶囊获得核心

专利授权；速效救心丸成功入选天津市现代中药新质生产力科技创新工程项目；已启动 SCRM 系统方案，完成营销数据分析平台首阶段建设，打造“看板+洞察”核心体系；完成两项院内制剂转新药项目的中试研究；老配本院内制剂注册项目完成两个品种临床病例入组；基于“京万红因子”（京万红软膏原材料有效运用于护肤品的核心组合物）开发出适应于敏感肌的“舒韧安肤系列产品”已于 7 月上市。

Since 2024, the Company has advanced multiple initiatives to enhance new quality productive forces (新质生产力), improve quality standards and drive efficiency. Key achievements to date include:

(i) the implementation of the unified internal control standards project for Chinese medicinal materials, streamlining and standardising key quality control processes, and based on product characteristics, the establishment of 46 procurement standards for Chinese medicinal materials which are stricter than the standards set out in the Chinese Pharmacopoeia;

(ii) the commencement of the compilation of the Tianjin Pharmaceutical Da Ren Tang Quality Standards for Chinese Medicinal Materials (2025) (《津药达仁堂中药材质量标准 (2025)》), with draft quality standards for 100 varieties already completed;

(iii) the establishment of two (2) new “three-without and one-complete” bases (referring to no pollution, no harmful substances, no residue, and full traceability) for *Coptis chinensis* (黄连, Chinese goldthread) and *Magnolia officinalis* (厚朴, Magnolia bark) in 2024, and the passing of the extended inspection conducted by the Tianjin Medical Products Administration (天津市药监局) for the *Lonicera japonica* (金银花, honeysuckle) GAP (Good Agricultural Practice) base in the first half of 2025;

(iv) the completion of the “elderly-friendly” reform of the package inserts for five (5) products, which have been launched in the market, incorporating functions such as digital human video guides, electronic instructions and voice broadcasts;

(v) the completion of project approval, stability studies on extended shelf life (36 months), regulatory filing and approval for six (6) products, and their subsequent launch in the market;

(vi) the completion of an evaluation of the recovery plan for 33 dormant product varieties;

(vii) the completion of production of Renshen Jianpi Wan (人参健脾丸) and Liuwei Dihuang Wan (六味地黄丸) under the “large pill to small pill” reform project covering eight (8) varieties of traditional Chinese pills;

(viii) the grant of core patent authorisation for Biqi Jiaonang (痹祺胶囊);

(ix) the inclusion of Suxiao Jiuxin Wan (速效救心丸) in Tianjin’s Modern Chinese Medicine “New Quality Productive Forces” Technology Innovation Project (天津市现代中药新质生产力科技创新工程项目);

(x) the initiation of the SCRM (Social Customer Relationship Management) system project and the completion of the first phase of its marketing data analytics platform, establishing a core “dashboard + insights” capability;

(xi) the completion of pilot studies for two (2) in-hospital preparations under new drug projects;

(xii) the completion of clinical case enrolment for two (2) varieties under the legacy in-hospital preparation registration programme; and

(xiii) the development of the “Shuren Anfu” (舒韧安肤) product line for sensitive skin, leveraging the “Jingwanhong Factor” (京万红因子) (a core compound extracted from Jingwanhong ointment for skincare applications), which was launched in July 2025.

2025 年，公司将继续巩固推进前述工作，提升新质生产力，提质增效等工作。

Looking ahead to 2025, the Company will continue to consolidate and advance the above initiatives, further enhancing new quality productive forces (新质生产力) and improving efficiency and effectiveness.

三、关注股东回报，共享发展红利

III. Commitment to Shareholder Returns and Sharing the Benefits of Growth

2024 年 7 月，公司实施了 2023 年度现金分红方案，即每 10 股派发现金红利 12.80 元，合计派发 9.86 亿元。2025 年 7 月，公司实施了 2024 年度现金分红方案，即每 10 股派发现金红利 12.80 元，合计派发 9.86 亿元。自 2001 年公司在上交所上市以来，已累计现金分红 51.17 亿元，平均分红率 50.69%，派息融资比 414.01%。

In July 2024, the Company implemented its 2023 cash dividend distribution plan, paying RMB12.80 (inclusive of tax) for every 10 shares, with total cash dividends amounting to approximately RMB986 million. In July 2025, the Company implemented its 2024 cash dividend distribution plan, again paying RMB12.80 (inclusive of tax) for every 10 shares, with total cash dividends also amounting to approximately RMB986 million. Since its listing on the SSE in 2001, the Company has cumulatively distributed cash dividends of approximately RMB5,117 million, representing an average dividend payout ratio of approximately 50.69% and a dividend-to-financing ratio of approximately 414.01%.

未来公司将在持续创造价值的基础上，强化股东回报，遵照证监会《上市公司监管指引第 3 号——上市公司现金分红》，并响应证监会有关分红倡议之精神，落实《津药达仁堂集团股份有限公司 2023-2025 年股东回报规划》，并在未来期间持续做好股东回报规划的审议和披露工作。在做好资本开支规划的情况下，尽可能以现金分红方式，直接回报股东。

Looking ahead, the Company will continue to enhance shareholder returns while creating long-term value. The Company will implement the “Scheme on Return of Investment to Shareholders from 2023 to 2025” (津药达仁堂集团股份有限公司 2023-2025 年股东回报规划) in accordance with the *Regulatory Guideline No. 3 for Listed Companies - Distribution of Cash Dividends by Listed Companies* (《上市公司监管指引第 3 号-上市公司现金分红》) promulgated by the China Securities Regulatory Commission (the “CSRC”) and in line with the CSRC’s dividend initiatives. The Company will continue to review and disclose its shareholder returns plan on a timely and regular basis. While ensuring adequate capital expenditure planning, the Company will, where possible, prioritise cash dividends as a means of directly returning value to shareholders.

四、加强投资者沟通，提升公司透明度

IV. Strengthening Investor Communication and Enhancing Corporate Transparency

2024 年至今，公司在及时准确公告的基础上，不断提高公告可读性，在定期报告之外，做好《可持续发展报告 (ESG 报告)》等多维度信息披露工作，通过图表提高可读性，公司获得 2023-2024 年度信

息披露 A 级评价。公司积极组织定期报告业绩说明会，提高投资者热线、互动平台、电子邮箱、现场调研接待水平，并充分利用股东会等契机，组织投资者与管理层直面交流，面向投资者组织参观车间，走进达仁堂博物馆，体验非遗，中医义诊，品鉴大健康食品等多维度感受达仁堂风貌和中医药文化的各项活动，公司股东反馈良好，参加热情不断提升。公司在 2024 年度积极参与和组织了投服中心组织的“了解我的上市公司——走进达仁堂”等活动，在 2025 年开启了“节气养生——走进达仁堂”系列活动，面向投资者开放实地调研。

Since 2024, the Company has continued to strengthen its investor relations efforts on the basis of timely and accurate announcements, while improving the readability of disclosures. In addition to its periodic reports, the Company has published its Sustainability Report (ESG Report) and other multi-dimensional disclosures, enhancing readability through charts and graphics. The Company received an A rating from the SSE for its information disclosure for the year 2023–2024. The Company organised performance briefings for its periodic reports, enhanced investor hotline services, online interactive platforms, a dedicated investor relations email channel, and on-site investor visits, and made full use of general meetings as opportunities for direct communication between investors and management. It also organised investor site visits to production facilities, the Da Ren Tang Museum, and cultural activities including intangible cultural heritage experiences, traditional Chinese medicine consultations, and health food tastings. In 2024, the Company participated in and organised activities such as “Understand My Listed Company – Visit Da Ren Tang” (了解我的上市公司—走进达仁堂) initiated by the China Securities Investor Services Centre (中国证券投资者服务中心). In 2025, the Company launched the “Health Preservation by Solar Terms – Visit Da Ren Tang” (节气养生—走进达仁堂) series of investor events, further expanding opportunities for on-site visits for investors. Shareholder feedback has been positive, with growing participation and enthusiasm.

做好股东信息回复的同时，公司持续关注股东对于公司治理、经营业务的意见建议，股东建议及时反馈至公司管理层和相关部门，保证股东参与公司治理的权利，发挥股东管理才智。2025 年上半年，公司开通了董事长邮箱 (dongshizhang@jydr.com.cn)，也增加了股东参与公司治理的渠道。

In addition to responding to shareholders’ enquiries, the Company has continued to take into account shareholders’ views on corporate governance and business operations. Shareholders’ suggestions are promptly relayed to management and relevant departments, ensuring shareholders’ rights to participate in corporate governance and to provide constructive input. In the first half of 2025, the Company launched a “Chairman’s Mailbox” (email: dongshizhang@jydr.com.cn), further expanding channels for shareholders’ participation in governance.

2025 年，公司将继续做好信息披露，业绩说明会，“节气养生——走进达仁堂”等工作，加强投资者沟通，提升公司透明度，做好股东建议的搜集整理和落实工作。

Looking ahead to 2025, the Company will continue to enhance its disclosure practices and performance briefings, and will also continue the “Health Preservation by Solar Terms – Visit Da Ren Tang” (节气养生—走进达仁堂) activities, while strengthening investor communication, improving transparency, and collecting, reviewing and following up on shareholders’ suggestions.

五、规范治理方面，做好投保工作

V. Strengthening Corporate Governance and Enhancing Investor Protection

2024 年至今，公司将不断跟踪监管法规和政策指引，做好内部制度更新修订，制定、修订和落实《独立董事制度》、《投资者关系管理制度》、《关联交易管理制度》等制度，更加注重保护投资者，特别是中小投资者的合法权益，重视股东在平等知情，分红回报，决策建议等方面的权利。

Since 2024, the Company has continued to monitor regulatory developments and policy guidelines, and has updated and revised its internal policies accordingly. The relevant policies, including the Independent Director System (独立董事制度), the Investor Relations Management Policy (投资者关系管理制度), and the Interested Person/ Related Party Transactions Management System (关联交易管理制度), have been formulated, revised and implemented to safeguard the legitimate rights and interests of investors, in particular minority shareholders, and to protect shareholders' rights including equal access to information, dividend returns and participation in decision-making.

2025 年, 公司将不断跟踪学习监管法规和政策指引, 并做好内部制度更新修订, 以法规为准绳, 以制度为指引做好公司规范治理, 维护股东的各项权利。

Looking ahead to 2025, the Company will continue to monitor and keep abreast of regulatory requirements and policy guidelines, and will further update and revise its internal policies. Guided by laws and regulations as the foundation, and internal policies as the framework, the Company will continue to strengthen corporate governance and safeguard the rights of all shareholders.

六、强化“关键少数”, 加强正向激励

VI. Strengthening “Key Few” and Enhancing Positive Incentives

2024 年至今, 公司强化组织公司控股股东和董事、监事、高管等关键少数, 通过参加交易所、上市公司协会等组织的合规培训, 学习法规制度。公司董事会审议通过《公司超额激励专项管理办法》, 强化正向激励, 加强关键经营人员与股东保持公司发展利益的一致性。完成健康科技平台中后台人员薪酬标准化, 绩效关联经营指标, 推行分布考核, 强化“干好干坏不一样”导向, 试点效能突破, 在研发域、营销域、人力资源管理开展流程速赢试点。

Since 2024, the Company has strengthened compliance training for its “key few”, including the controlling shareholder(s), directors, supervisors and senior management personnel, through participation in training programmes conducted by stock exchanges, associations of listed companies and other organisations, in order to enhance their knowledge of the applicable laws and regulations. The Board approved the Special Administrative Measures for Excess Incentives of the Company (公司超额激励专项管理办法), thereby reinforcing positive incentives and further aligning the interests of key management personnel with those of shareholders in the Company's development. In addition, the Company standardised compensation for mid- and back-office staff of its healthcare technology platform, linked performance appraisals with operating indicators, and implemented differentiated assessments to reinforce a “performance matters” orientation. Pilot efficiency-enhancement initiatives were also carried out, with “quick-win” process optimisation projects launched in research and development, marketing and human resources management.

2025 年, 公司将继续组织好关键少数的合规学习工作, “按照做精后台, 做强中台, 做多前台”的理念, 前中后台向联合作战转变。公司将不断探索引入其他行之有效的激励和监督管理工具。公司推动构建以客户为中心的端到端流程体系, 推动以局部最优的职能目标导向, 向以整体最优的组织目标转变, 助推公司高质量发展。

Looking ahead to 2025, the Company will continue to organise compliance trainings for its key personnel and promote the integration of the front, middle and back offices under the concept of “optimising the back office, strengthening the middle office, and expanding the front office”, with a transition towards more collaborative operations. The Company will also explore additional effective incentive and supervisory mechanisms. In addition, the Company will promote the establishment of an end-to-end process system centred on consumers, shifting from departmental-level optimisation of

functional objectives to organisation-wide optimisation, to support the Company's high-quality development.

公司“提质增效重回报”行动方案涉及到的前瞻性陈述和战略规划，未来可能会受到宏观政策、行业形势等因素影响，存在一定的不确定性，不构成公司承诺，敬请广大投资者注意投资风险。

Forward-looking statements and strategic plans contained in the Company's Action Plan for "Quality Improvement, Efficiency Enhancement and Focus on Shareholder Returns" may be subject to uncertainties arising from macroeconomic policies, industry conditions and other factors. These statements do not constitute commitments by the Company, and investors are advised to exercise caution and be mindful of investment risks.

公司将持续跟踪评估“提质增效重回报”行动方案的执行情况，践行上市公司责任，回馈广大投资者的支持和关注。

The Company will continue to monitor and evaluate the implementation of the "Quality Improvement, Efficiency Enhancement and Focus on Shareholder Returns" Action Plan, fulfil its responsibilities as a listed company, and remain committed to delivering returns to investors and acknowledging their continued support.